The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of pre-existing thyroid autoimmunity with the development of thyroid dysfunction induced by nivolumab.
 
Shiro Kimbara
No Relationships to Disclose
 
Yutaka Fujiwara
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AbbVie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Lilly; Merck Serono; MSD; Novartis
 
Shintaro Iwama
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical
 
Ken Ohashi
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical
 
Aya Kuchiba
No Relationships to Disclose
 
Hiroshi Arima
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical
 
Naoya Yamazaki
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical; Takara Bio
Research Funding - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical; Takara Bio
Other Relationship - Bristol-Myers Squibb; MSD; Novartis; Novartis
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Group; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Pfizer
Research Funding - Astellas Pharma; Eisai; Gilead Sciences; Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; REGENERON
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca; Ono Pharmaceutical